Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: EU Agencies Update On ‘Mix-And-Match’ & Booster Vaccines, UK Expands Human Challenge Trial

Executive Summary

ExeVir’s potential antibody therapy against variants of concern is moving into clinical trials, and Irish researchers say an abandoned glioblastoma candidate compound could prevent respiratory and cardiovascular damage in COVID-19 patients.

You may also be interested in...



Coronavirus Notebook: UK To Start World’s First COVID-19 Challenge Study, Janssen Files Its Vaccine For EU Approval

Cuba is about to begin Phase III trials with one of its four homegrown coronavirus vaccines, Australia has provisionally approved the AstraZeneca/Oxford University product, and the EU has upped its orders from Pfizer/BioNTech and Moderna.

New Lease Of Life For Merck Serono Reject Cilengitide

Basing a company around a high-profile failed drug candidate is not for the faint hearted, but that's exactly what Dr. John March is doing with Merck Serono reject cilengitide. Scrip asked him what it will take to turn the cilengitide story around.

UCB’s Bimekizumab Gets Fast-Track Funding For Severe Psoriasis In England

It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel